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Studies on PBMC samples from HIV-1 infected patients have shown that despite substantial number of
HIV speciﬁc CTLs, these patients gradually progress to AIDS. The present study was conducted to
determine whether this paradox was secondary to the inﬂuence of protease inhibitors being utilized by
these patients. Thus, aliquots of PBMC samples from 10 HIV infected humans with no prior history of
anti-retroviral drug therapy (ART) and 6 HIV-infected patients that had been on HAART for .1 year
were analyzed for the frequency of HIV-1 Nef and Gag dominant peptide speciﬁc tetramerþ cells,
respectively. The tetramerþ PBMCs were analyzed for their ability to synthesize speciﬁc peptide
induced IFN-g utilizing both the ELISPOT and the intracellular cytokine (ICC) assays. Results of the
studies showed that there was an overall correlation between the frequency of Nef and Gag peptide
tetramerþ cells and the frequency of IFN-g synthesizing cells as assayed by either ICC or ELISPOT
assay, markedly reduced values of IFN-g synthesizing cells per unit tetramerþ cells were noted in both
group of patients. These data suggest that the frequency of HIV-speciﬁc CD8þ T cells is maintained
during the chronic phase of infection, their ability to function is compromised and is not a reﬂection of
ART. While the addition of IL-2, anti-CD40L and allogeneic cells led to partial increase in the ability of
the tetramerþ cells to synthesize IFN-g, the addition of IL-4, IL-12, anti-CD28 or a cocktail of anti-
TGF-b, TNF-a and IL-10 failed to augment the IFN-g response.
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INTRODUCTION
It is generally accepted that control of viremia in HIV-1
infected individuals is mediated to a large part by virus
speciﬁc cytotoxic CD8þ T effector cells (Koup et al.,
1994; Klein et al., 1995). This important role for CD8þ
CTLs is supported by results of a number of studies.
These studies include the ﬁnding that there is a strong
correlation between the level of decline in plasma viremia
and the level of virus speciﬁc CD8þ CTL function
during the acute viremia period (Borrow et al., 1994;
Koup et al., 1994). Secondly, it is clear that while
progression to disease in HIV-1 infected patients is
accompanied by loss of virus speciﬁc CTL function
(Carmichael et al., 1993; Rinaldo et al., 1995), induction
and maintenance of strong virus speciﬁc CTL function is
one of the hallmarks of HIV-1 infected patients who are
classiﬁed as long term non-progressors (Klein et al.,
1995; Harrer et al., 1996a,b). Further support for a
prominent role for virus speciﬁc CD8þ effector CTLs
came from the ﬁnding that select individuals who were
highly exposed to HIV-1 but had undetectable levels of
virus in their blood, appeared to demonstrate a broad
HIV-1 speciﬁc CTL effector cell population in their
peripheral blood mononuclear cells (PBMCs) (Rowland-
Jones et al., 1995; Fowke et al., 1996). Unequivocal
evidence for an important role that CD8þ effector T
cells play in lentiviral infection came from the ﬁnding
that depletion of this cell lineage in SIV infected rhesus
macaques in vivo with the use of a depleting monoclonal
anti-CD8 antibody, led to marked increases in viral loads
associated with progression to disease (Schmitz et al.,
1999; Jin et al., 1999).
A prominent role for CD8þ CTL effector function in
the clearance of a number of other viral infections in both
humans and a variety of experimentally infected animals
has long been established (Riddell et al., 1992; Guidotti
et al., 1996; Chisari, 1997). To a large extent, such
effector CTL function has been measured by conventional
bulk functional in vitro re-priming CTL assays in which
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CD8þ T cell containing PBMCs were co-cultured in
varying ratios with the appropriate virus infected radio-
actively labeled autologous target cells. Release of
radioactivity was utilized as a measure of lytic activity
of the effector CD8þ cytotoxic T cell in such assays and
the ratio of effector: target cell utilized as a relative
assessment of the frequency of viral antigen speciﬁc
CD8þ T cells (Walker et al., 1987). Use of limiting
dilution assays accompanied by use of speciﬁc virally
encoded synthetic peptides to pulse the target cells
provided a somewhat better assessment of the precursor
frequency of viral antigen speciﬁc effector CD8þ T cells
(Carmichael et al., 1993; Koup et al., 1994). These type of
assays, however, did not provide a clear picture on the true
frequency of peptide speciﬁc effector CD8þ T cells
since such assays were designed to measure functional
activity. An important and major scientiﬁc breakthrough
was achieved by the seminal ﬁndings from the laboratory
of Dr Mark Davis with the discovery that speciﬁc
peptide bearing ﬂuorescently tagged tetrameric conjugates
of recombinant MHC class I molecules could be utilized
as probes for the identiﬁcation of peptide speciﬁc MHC
class I restricted CD8þ T cells by ﬂow cytometry
(Altman et al., 1996). The advent of this technology
was soon followed by its use for enumerating the
frequency of HIV-1 peptide speciﬁc MHC class I
restricted CD8þ CTL and the ﬁnding that there was an
inverse correlation between the frequency of such HIV-1
peptide-tetramer binding CD8þ T cells and the level of
plasma viremia (Ogg et al., 1998). Of importance was the
ﬁnding that the frequency of such peptide-tetramer
binding CD8þ T cells correlated well with the in vitro
cytotoxicity assay. These last two pieces of evidence
conﬁrmed the previously held view of an important role
for CD8þ CTL in the control of viremia in human HIV-1
infected individuals. While tetramer technology paved the
way for the precise enumeration of antigen speciﬁc T
cells, further advances were being made on methodologies
to assess antigen speciﬁc T cell function by the
measurement of cytokine synthesis upon exposure of the
T cell receptor to its cognate peptide bearing MHC ligand.
These include the ELISPOT assay (Lalvani et al., 1997)
and the intracellular synthesis of intracellular cytokines
(ICC) such as IFN-g by CD8þ T cells as a correlate of
antigen speciﬁc effector function (Betts et al., 2000).
These ELISPOT and ICC technologies were soon used in
conjunction with the tetramer analysis and these are the
assays that continue to be most often utilized for the
measurement of antigen speciﬁc T cell function (Appay
et al., 2000; Goepfert et al., 2000; Goulder et al., 2000).
Results with the use of such assays in PBMCs
samples from HIV-1 infected individuals showed that
there was a progressive decline in HIV-1 speciﬁc peptide-
tetramerþ cells as patients developed clinical disease
(Rinaldo et al., 2000). Since these studies, a number of
additional studies utilizing similar tetramer technology
and ICC analysis have provided conﬂicting data on
the frequency of such HIV speciﬁc tetramerþ cells and
function (Appay et al., 2000; Shankar et al., 2000;
Kostense et al., 2001). Thus, while some studies reported
that most HIV speciﬁc tetramerþ CTLs synthesize IFN-g
but had relatively low levels of perforin (Appay et al.,
2000), others documented that ,25% of the HIV speciﬁc
tetramerþ cells synthesized IFN-g (Shankar et al., 2000).
The low frequency of IFN-g synthesizing tetramerþ cells
could be increased by the supplementation of the culture
media with interleukin-2 (Shankar et al., 2000). Each of
these studies, however, utilized PBMCs samples from
patients who were undergoing various chemotherapeutic
regimens including patients who were being administered
protease inhibitors that besides their anti-viral effect could
also potentially inﬂuence assays that involve antigen
processing and presentation and thus inﬂuence the
outcome of the studies (Andre et al., 1998). The present
study was therefore undertaken utilizing PBMC samples
from patients with no previous history of anti-retroviral
drug therapy (ART) and for comparison PBMCs from
patients with .1 year history of HAART to address
this issue. Results of these studies constitute the basis of
this report.
MATERIALS AND METHODS
Study Population
The studies performed herein were approved by the Ethics
Committees, Faculty of Medicine Siriraj Hospital,
Mahidol University, Bangkok, Thailand and Emory
University School of Medicine, Atlanta, GA. Each study
volunteer was explained the nature of the study and
appropriate informed consent was obtained prior to the
enrollment of the patients in the study. Peripheral blood
samples were obtained from a total of 11 non-HIV
infected and 24 stage 1 (WHO nomenclature) HIV-1
infected patients in Thailand and 6 archived HLA-A*0201
HIV-1 infected PBMC samples from patients who had
been on ART for .1 year at the Emory University.
An aliquot of these cryopreserved PBMCs were subjected
to molecular MHC class I typing (Tissue Typing
Laboratory, Emory University Hospital, Atlanta, GA).
Four of the 11 non-HIV infected control and 10 of the 24
HIV-1 infected patient samples were found to express the
HLA-A*1101 MHC class I allele. None of these 10
patients received any antiretroviral chemotherapy prior to
the study. Routine CBC based absolute lymphocyte counts
and T cell subset analysis by ﬂow cytometry were
determined on aliquots of a blood sample from each
patient (Table I). Blood samples were separated on Ficoll-
Hypaque (Histopaque 1077; Sigma, St Louis, MO)
gradients to obtain PBMC. Aliquots of the PBMCs were
cryopreserved in media containing 20% fetal bovine
serum (FBS) with 10% DMSO and stored at 21808C prior
to thawing and use in the analysis of the peptide-MHC
tetramer staining and ELISPOT assays.
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The following monoclonal antibodies (mAbs) were
commercially obtained and utilized at the concentration
recommended by the respective manufacturer in the
studies reported herein: PerCP-conj. anti-human CD8
(Becton Dickinson Biosciences, San Jose, CA); APC-
conj. anti-human CD3 and FITC-conj. anti-IFN-g
(Coulter, Miami, FL). The anti-human CD28 and CD49d
(puriﬁed) were purchased from Pharmingen (San Diego,
CA) and each used at a ﬁnal concentration of 1mg/ml.
Brefeldin A (BFA: GolgiPluge) and Monensin (GolgiS-
top
w) were also obtained from Pharmingen and used at
10mg/ml. Staphylococcal Enterotoxin B (SEB) was
purchased from Sigma and used at 10mg/ml. The HLA-
A*1101-restricted epitope from the Nef protein of HIV-1
clade E (QVPLRTMPYK) and the HLA-A*0201-
restricted HIV-1 clade B Gag epitope (SLYNTVATL)
were synthesized by standard ﬂuorenylmethoxycarbonyl
chemistry by the Microchemical facility, Emory Univer-
sity. The peptides were used at 10mg/ml.
Cell Surface Staining with Peptide-MHC Tetrameric
Complex
Peptide-MHC tetrameric complex can be used to directly
detect antigen speciﬁc T cells by ﬂow cytometry (Altman
et al., 1996). The HLA A*1101 immuno-dominant Nef
peptide “QVPLRTMPYK” and the HLA-A*0201 domi-
nant HIV-1 Gag peptide “SLYNTVATL” were utilized to
prepare the tetrameric complex (heretofore referred to as
A11Nef and A2Gag) formed by streptavidin conjugated
with phycoerythrin (PE) under the supervision of
Dr Nattawan Promadej (Division of HIV/AIDS, Centers
for Disease Control and Prevention, Atlanta, GA). Brieﬂy,
recombinant MHC class I heavy chains isolated from
HLA-A 1101 and HLA-A0201 individuals were refolded
with the appropriate peptides and b2-microglobulin to
form peptide-MHC tetrameric complexes. The MHC
heavy chains were engineered to contain a biotinylation
site at the COOH terminal. The monomer constructs were
utilized to form tetrameric complexes by the addition of
streptavidin conjugated PE. Aliquots of the cryopreserved
PBMCs were thawed, washed two times at 500g for 5min
each in RPMI medium (RPMI 1640) containing 10% heat
inactivated fetal bovine serum, 1% penicillin–strepto-
mycinand 2mM L-glutamine (all reagents were purchased
from GIBCO, Grand Island, NY). The cells were then
re-suspended in medium at 1 £ 106 cells/ml and incubated
with the PE-conj. A11nef or A2Gag tetrameric complex,
anti-human CD8 PerCP and anti-human CD3 APC mAbs
for 30min at 48C. Finally, the sample was washed using
washing buffer (PBS with 2% fetal bovine serum) and
ﬁxed in 1% paraformaldehyde in PBS and stored at 48C
until ﬂow cytometric analysis. The percentage of A11Nef
or A2Gag tetramerþ cells among the CD3þ CD8þ T
cells population were determined on a FACSCaliber ﬂow
cytometer (BDB) using Cellquest software. Data from at
least 200,000 cells gated on the lymphocyte population
were acquired and subjected to analyses.
Enumeration of IFN-g Synthesizing Cells by the
ELISPOT Assay
CTL-M200 (Cellular Technology; Cleveland, OH) 96-
well plates were coated overnight at 48C with 50mlo f
anti-IFN-g mAbs, clone 1-D1K, (Mabtech: Stockholm,
Sweden) at 5mg/ml. The antibody-coated plates were
washed four times with PBS and blocked with 100mlo f
RPMI medium (RPMI 1640) containing 10% heat
inactivated fetal bovine serum, 1% penicillin–strepto-
mycin and 2mM L-glutamine for 1h at 378C. The
appropriate PBMCs at 2 £ 105 cells in 200ml medium
were added to duplicate wells and incubated for 36h at
378C/5%CO2 with either the HLA-A*1101 restricted Nef
peptide or the HLA-A*0201 restricted Gag peptide
described above (10mg/ml). PBMC incubated with PHA
(2mg/ml) were used as a positive control and cells without
any peptide or PHA were used as a negative control. The
plates were then washed four times with washing buffer
consisting of PBS containing 0.05% Tween-20 (Sigma).
TABLE I Value of CD4þ and CD8þ T cell subset
Patients CD4 count/ml %CD4 CD8 count/ml %CD8 Ratio
No ART (A11) P14 318 10.60 1633 54.45 0.195
P17 241 14.20 917 54.05 0.263
P19 277 10.55 1773 67.45 0.156
P24 221 14.90 994 67.00 0.222
P27 309 16.60 864 46.40 0.358
P33 328 9.20 1802 50.60 0.182
P38 404 13.20 2176 71.10 0.190
P39 178 7.60 1820 77.60 0.100
P43 311 17.25 873 48.50 0.360
P46 229 11.95 1212 63.30 0.190
ART (A2) P50 412 17.19 1728 72.12 0.238
P57 506 18.53 1879 68.82 0.269
P59 578 19.32 2124 71.01 0.272
P64 492 26.56 1024 55.29 0.480
P67 502 22.41 1821 70.11 0.320
P79 435 25.16 998 57.72 0.436
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IFN-g mAbs, clone 7-B6-1, (Mabtech, Nacka, Sweden)
in PBS containing 1% fetal bovine serum and 0.05%
Tween-20 was added. After incubation for 3h at
378C/5%CO2, the plates were washed with washing
buffer as above and 50ml of streptavidin conjugated
alkaline phosphatase (Mabtech) was added at a dilution of
1:1000 in PBS containing 1% fetal bovine serum and
0.05% Tween-20. This was followed by 1h incubation at
378C/5%CO2. The plates werewashed again with washing
buffer and 50ml of 1-Step NBT/BCIP (Pierce Chemicals,
Rockford, IL) was then added to each well. The reaction
was stopped by washing three times with sterile water.
The number of spots was enumerated utilizing the
Immunospot analyzer (Cellular technology). The number
of spots per 10
6 cells was calculated from the average of
duplicate wells subtracting the average spots obtained
with the negative control run in parallel.
Antigen Stimulation and ICC Staining
of Tetramer1 Cells
PBMC at 1 £ 106 cells/ml were pre-stained with the
tetrameric complex and incubated in a 5ml polypropylene
tube. The cultures were incubated upright for 30min at
378C/5%CO2 followed by washing in medium. The cells
were resuspended in medium and stimulated with
10mg/ml of the same HIV peptide as used for the
formation of the tetrameric complex in the presence of
anti-human CD28 and CD49d mAbs (each at 1mg/ml) for
2h at 378C/5%CO2. PBMCs stimulated with SEB
(10mg/ml) were used as a positive control and cells
without any peptide or SEB were used as a negative
control. Both BFA and monensin (10ug/ml) were added
for the ﬁnal 4h. After the total 6h of incubation, 100mlo f
20mM EDTA in PBS was added to each of the stimulated
and unstimulated samples and the samples incubated in
the dark for 15min at room temperature (RT). Samples
were then ﬁxed in 2ml of 1 £ FACSe Lysing Solution
(BDIS) and incubated in the dark for 10min at RT
followed by centrifugation at 500g for 5min. Cells were
washed in washing buffer and permeabilized with 0.5ml
of 1 £ FACSe Permeabilizing Solution (BDIS)
for 10min at RT in the dark. After permeabilization,
cells were washed by adding 2ml of washing buffer
and centrifugation at 500g for 5min. Cell surface and
intracellular staining was performed following the
addition of an antibody cocktail consisting of anti-
human CD8 PerCP, CD3 APC and anti-IFN-g FITC
followed by incubation in the dark for 30min at RT. After
staining, the cells were washed and ﬁxed in 1%
paraformaldehyde in PBS pH 7.4 and stored at 48C until
ﬂow cytometric analysis were performed.
Flow Cytometric Analysis of ICC Production
Six-parameter analysis of the above stained samples was
performed on a FACSCaliber ﬂow cytometer (BDB) using
Cellquest software. Data from at least 200,000 cells gated
on the lymphocyte population were acquired and a
lymphogate was done to include only viable lymphocytes.
Data were displayed as two-color dot plot (FITC vs PE) to
measure the percentage of the double positive (IFN-g þ /
tetramerþ ) cells within the CD3þ CD8þ T cells
population (upper right quadrant, see Fig. 1 for details).
An unstimulated control was used to set the quadrant gate.
The percentage of IFN-g sysnthesizing tetramerþ T cells
was calculated within the CD3þ CD8þ tetramerþ T
cells population.
Reconstitution Experiments
PBMCs samples only from the select HLA-A*1101 HIV-1
infected individuals were utilized for these studies. The
PBMCs ð1 £ 106=mlÞ were stained with the A11Nef
tetramer as described above and then cultured in the
presence or absence of either recombinant human IL-2
(10U/ml, courtesy Hoffman LaRoche, Nutley, N.J.), anti-
CD40L (10mg/ml, B–D Pharmingen, San Jose, CA),
allogeneic irradiated PBMC from a healthy human
volunteer (5000 rads, 1 £ 106=ml), human recombinant
IL-4 (10U/ml, Biosource Int., Camarillo, CA), recombi-
nant human IL-12 (Biosource Int., Camarillo, CA), or a
cocktail of anti-TGF-b,a n t i - T N F - a and anti-IL-10
FIGURE1 Comparisonbetweenthenumberofspotformingunitper10
6
PBMC (SPF/10
6) by ELISPOT, IFN-g producing CD3þ CD8þ T cells
per 10
6 PBMC by ICS and the frequency of A11Nef tetramerþ cells per
10
6 PBMC from ART naı ¨vepatient (A) and A2Gag tetramerþ cells from
ART treated patient (B).
N. ONLAMOON et al. 290(each at 10mg/ml, B–D Pharmingen, San Jose, CA) and
with or without the Nef peptide (10mg/ml). Following
incubation for 2h, both BFA and monensin were added
(10mg/ml) for the last 4h. The cultures were washed and
the frequency of A11nef tetramerþ cells synthesizing
IFN-g determined using ﬂow cytoﬂuorometry as
described above. A minimum of 200,000 cells was
analyzed to calculate the frequency of IFN-g synthesizing
cells. Results are expressed as the net frequency of Nef
peptide speciﬁc IFN-g synthesizing cells by deducting the
values obtained from cultures incubated without the Nef
peptide from the ones incubated with the Nef peptide and
the identical reconstituting agents.
To study cytokine production ability after CD4þ T
cells depletion, PBMCs from 2 HIV-1 infected HLA-
A*1101 patients were subjected to depletion of CD4þ T
cells using anti-CD4 coated immunobeads (Dynal Corp.,
Lake Success, NY) at a ratio of 4beads per CD4þ Tcells.
Following depletion, the cells were washed and utilized
for the analysis of A11Nef tetramerþ CD3þ CD8þ T
cells that synthesized IFN-g as outlined above.
Statistical Analysis
The Pearson correlation coefﬁcient test was used to
analyze for the association observed between different
parameters with a value of p , 0:05 being considered
signiﬁcant.
RESULTS
Frequency Analysis of HIV-1 Speciﬁc CD81 T Cells
as Determined by Tetramer Analysis
In the present study, the A11Nef tetramer reagent was
utilized to determine the frequency of A11Nef tetramerþ
cells among the CD3þ CD8þ T cell sub-population in
the PBMCs from 4 control non-HIV infected and 10
retroviral drug naı ¨ve HIV-1 infected patients and the
A2Gag tetramer reagent in the same subset of PBMCs
from 6 HIV-1 infected patients with a history of ART for
.1 year. The frequency of tetramer-binding cells in the 4
control non-HIV infected HLA-A*1101 individuals was
,0.03% (data not shown) and ranged from 0.3 to 1.52%
(0:77 ^ 0:37; mean ^ SD) in PBMCs samples from the 10
HIV-1 infected patients (Table II). PBMCs from three of
these 10 patients showed a frequency of A11Nef tetramer-
binding cells of 1% or greater. In conﬁrmation with
previous studies (Ogg et al., 1998), the results showed a
negative correlation with absolute CD4þ T cell count
(R ¼ 0:927; p ¼ 0:0001) (data not shown). These data
indicate that the loss of CD4þ T cells is associated with
an increase in the frequency of HIV-1 speciﬁc CD8þ T
cells. The frequency of A2Gag tetramerþ cells in the
PBMCs samples from the HIV-1 infected patients on ART
for .1 year ranged from 0.22 to 1.79 (0:89 ^ 0:62;
mean ^ SD). In contrast, a positive correlation with
absolute CD4þ T cell count was observed in these
patients. This correlation was not statistically signiﬁcant
(R ¼ 0:794; p ¼ 0:0592) (data not shown). However,
when the results from the patient with low frequency of
A2Gag tetramerþ cells (P67) were excluded from the
analysis, the correlation became signiﬁcant (R ¼ 0:986;
p ¼ 0:0021) (data not shown). There was no statistical
difference in the frequency of tetramerþ cells in the HIV
infected ART drug naı ¨ve vs those with a history of .1
year of ART.
Frequency of HIV-1 Speciﬁc Peptide-MHC Tetramer-
binding Cells Correlated with Cytokine-producing
Cells as Determined by ELISPOT Assay
The functional activity of antigen speciﬁc T cells can be
determined at a single cell level by the ability of the cells
to synthesize select cytokines such as IFN-g invitro by the
ELISPOT assay (Lalvani et al., 1997). In this study, the
same A11Nef and the A2Gag restricted peptides as used
TABLE II Comparison analysis of the HIV peptide speciﬁc response as determined by tetramer staining, intracellular cytokine staining and ELISPOT
%Tetramer+
%IFN-gamma+
Patients in CD3+CD8+ in CD3+CD8+ in tetramer+ No. of tetramer/1 £ 10
6 No. of IFN-gamma/1 £ 10
6 SPF/1 £ 10
6
No ART (A11) P14 0.43 0.11 16.11 1892 501 125
P17 1.00 0.12 11.80 4253 469 108
P19 0.62 0.13 20.14 3711 776 383
P24 0.91 0.17 24.57 5122 887 433
P27 0.72 0.06 10.78 2807 269 333
P33 0.50 0.03 10.88 2249 201 323
P38 0.30 0.05 17.74 1772 281 80
P39 1.52 0.35 32.84 9293 2379 935
P43 0.61 0.14 14.12 1658 357 38
P46 1.13 0.32 27.44 4994 1483 790
ART (A2) P50 0.22 0.05 15.33 1667 536 327
P57 1.32 0.31 28.92 7758 2011 452
P59 1.79 0.34 34.56 9122 1956 259
P64 1.11 0.24 25.58 5676 922 314
P67 0.27 0.06 18.43 2242 256 426
P79 0.64 0.12 13.95 1723 412 339
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stimulate A11Nef and A2Gag speciﬁc T cells, respect-
ively, from the 2 groups of patients. The results were
expressed as spot forming cells (SPF) per 1 million cells
(SPF/10
6) of PBMCs. As seen in Table II, the frequency of
SPF/10
6 ranged from 38 to 935 (355 ^ 303; mean ^ SD)
in the ART naı ¨ve samples and ranged from 49 to 1256 in
the PBMCs from the patients on ART (445 ^ 494;
mean ^ SD). The results showed a negative correlation
with the absolute CD4þ T cell count (R ¼ 0:733;
p ¼ 0:0159) (data not shown). A positive correlation was
observed between the percentage of A11Nef and IFN-g
producing cells by ELISPOT (R ¼ 0:806; p ¼ 0:0049)
(data not shown). No correlation was observed between
the A2Gag tetramer-binding cells and IFN-g producing
cells by ELISPOT. This ﬁnding suggests that the A11Nef
and the A2Gag tetramerþ cells are functional since they
can synthesize IFN-g following recognition of the cognate
peptide.
Since the data on the frequency of tetramer binding
cells was derived by gating on the CD3þ CD8þ T cell
sub-population and the ELISPOT assay included analysis
of total unfractionated PBMCs, the frequency of tetramer
binding cells among all PBMCs (lymphocyte and
monocyte) was used to calculate the number of
tetramerþ cells per 1 million PBMC (Goepfert et al.,
2000). The number of tetramerþ cells/10
6 ranged from
1658 to 9293 (3775 ^ 2340; mean ^ SD) in the ART
naı ¨ve and 1667 to 9122 (4698 ^ 3285; mean ^ SD) in the
patients on ART, as shown in Table II. The number of
A11Nef tetramerþ cells/10
6 also showed a negative
correlation with absolute CD4þ T cell count (R ¼ 0:874;
p ¼ 0:001) (data not shown). These data indicate that a
large number of tetramerþ PBMCs failed to show
functional activity as determined by the ELISPOT assay.
The precise mechanism(s) for this dysfunction remains to
be determined.
HIV-1 Speciﬁc T Cells Detected by IFN-g Production
was Lower than the Frequency Detected
by Tetramer Staining
Although a correlation between tetramerþ cells and IFN-g
producing cells by ELISPOT assay in the PBMC of HIV
infectedpatientswasobserved,thenumberofHIV-1speciﬁc
TcellsestimatedbytheELISPOTassaywasalogfoldlower
than the absolute number of HIV-1 speciﬁc peptide-MHC
tetramerþ cells.ThisresultsuggeststhatmostoftheHIV-1
speciﬁc T cells are functionally inert. To investigate this
issuefurther,anICCstainingtechniquewasutilizedtomore
speciﬁcally enumerate and identify the cytokine producing
function of the CD3þ CD8þ T cells sub-population.
Following incubation, ﬁxation and permeabilization,
staining with anti-cytokine mAbs was performed. Data are
typically expressed as a frequency of cytokine producing
cells within phenotypically deﬁned T cell subsets. This
study used the same peptide as used for the ELISPOT
assay and for the enumeration of the tetramerþ cells.
The frequency of IFN-g producing CD3þ CD8þ Tc e l l s
as determined by ﬂow cytometric analysis of aliquots of
PBMC from the ART naive HIV infected patients ranged
from 0.03 to 0.35% (0:15 ^ 0:11%; mean ^ SD) and 0.05
to 0.34 (0:19 ^ 0:13; mean ^ SD) in PBMCs from patients
on ART (Table II). The data in ART naive also showed a
negative correlation with absolute CD4þ Tc e l lc o u n t
(R ¼ 0:808; p ¼ 0:0047) (data not shown) whereas a
positive correlation was observed in patients on ART. This
correlation was not statistically signiﬁcant (R ¼ 0:761;
p ¼ 0:0788) (data not shown). However, when the results
from the patient with low frequency of A2Gag tetramerþ
cells (P67) were excluded from the analysis, the correlation
became signiﬁcant (R ¼ 0:947; p ¼ 0:0146) (data not
shown). Furthermore, the frequency of IFN-g producing
CD3þ CD8þ T cells correlated with the frequency of
A11Nef and A2Gag tetramerþ T cells (R ¼ 0:864;
p ¼ 0:0013 and R ¼ 0:985; p ¼ 0:0004; respectively)
(data not shown). The frequency of IFN-g producing
CD3þ CD8þ T cells from the ART naive correlated with
thenumberofSPF/10
6asdetectedbyELISPOT(R ¼ 0:831;
p ¼ 0:0029). The results indicate a good correlation
between the frequency of HIV-1 speciﬁc tetramerþ T
cells, the number of IFN-g producing T cells by both the
ELISPOTand ICC assays.
In efforts to compare the number of HIV-1 speciﬁc T
cells by each method, the number of IFN-g þ cells per
1 million PBMCs was calculated from the frequency of
IFN-g producing CD3þ CD8þ T cells. The number of
IFN-g þ cells/10
6 PBMCs ranged from 201 to 2379
(760 ^ 688; mean ^ SD) in the ART naı ¨ve and 256 to
2011 (1016 ^ 782; mean ^ SD) in the patients on
ART. A positive correlation was observed between the
number of IFN-g þ cells/10
6 and the number of
tetramerþ cells/10
6 in both the ART naı ¨ve and the
patients on ART (R ¼ 0:930; p ¼, 0:0001 and
R ¼ 0:952; p ¼ 0:0033; respectively) (data not shown).
The number of IFN-g þ cells/10
6 correlate with the
number of SPF/10
6 as detected by ELISPOT in the ART
naive (R ¼ 0:899; p ¼ 0:0004) (data not shown). The
number of IFN-g þ cells/10
6 in the ART naive also
showed a negative correlation with the absolute number of
CD4þ T cells (R ¼ 0:789; p ¼ 0:0067) (data not shown).
These results suggest that while the estimated number of
HIV-1 speciﬁc T cells by the ICC assay was greater than
that obtained by the ELISPOT assay, the values obtained
by the ICC assay were still lower than the frequency of
tetramerþ cells in both group of patients (Fig. 1A and B).
These data suggest that a substantial number of
tetramerþ T cells may either have a functional disability
to produce IFN-g or that there is a difference in the
kinetics of IFN-g synthesis among the population of
tetramerþ cells. Paucity in the number of cells available
for analysis prevented us to study the issue of kinetics in
detail. However, in separate studies of a similar nature
utilizing PBMCs from Mamu-A01 þ SIV infected rhesus
macaques, which showed a similar decrease of IFN-g
synthesizing CD8þ p11C-M gag peptide tetramerþ
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kinetics of IFN-g synthesis by the immunodominant
p11C-M peptide Mamu-A-01 restricted and speciﬁc
tetramer binding CD8þ T cells. Results of this study
(in preparation) failed to demonstrate any meaningful
increases in the frequency of IFN-g synthesizing
tetramerþ cells following either a shorter or a more
prolonged incubation period providing indirect evidence
that our failure to detect IFN-g synthesis by HIV speciﬁc
tetramerþ cells is likely not due to kinetic differences.
Impaired Function of HIV-1 Speciﬁc T Cells can be
Detected by ICC Staining in Tetramer1 Cells
To directly determine the functionally inert HIV-speciﬁc
CTL at a single cell level, a combination method of
intracellular staining and tetramer staining of tetramerþ
cells was developed (Appay et al., 2000). Aliquots of
PBMCs from each of the 2 groups of patients (ART naı ¨ve
and those on ART) were stained using the peptide-
tetramer complexes prior to antigen stimulation. The pre-
staining of the A11Nef and the A2Gag speciﬁc tetramerþ
cells was followed by antigenic stimulation with the same
peptides as used in the formation of the tetramer reagents
for each set of patient samples. IFN-g synthesis within
tetramerþ cells was detected by the ICC assay. Only the
ﬂow cytometric proﬁle obtained with the A11Nef samples
are presented herein for the sake of brevity. The frequency
of IFN-g producing tetramerþ cells (upper right
quadrant, Fig. 2C) in a representative sample is illustrated.
As seen, most of the tetramerþ cells could not synthesize
IFN-g. It is possible that some of the IFN-g producing
cells could not be stained by the peptide-tetramer complex
possibly due to TCR down modulation following
activation (lower right quadrant). To calculate the
percentage of IFN-g producing tetramerþ T cells within
the tetramerþ population, only IFN-g producing cells
within the upper right quadrant were used (see Fig. 2D).
The percentage of IFN-g producing tetramerþ Tc e l l s
within the CD3þ CD8þ tetramerþ T cells ranged from
10.78 to 32.84 (18:64 ^ 7:55; mean ^ SD) in the ART
naı ¨ve patient samples and 13.95 to 34.56 (22:8 ^ 8:3;
mean ^ SD) in the samples from patients on ART. PBMCs
from 9/10 and 5/6 patients in the 2 groups showed ,30%
frequency of IFN-g producing tetramerþ Tc e l l s .T h e s e
data indicate that not all tetramerþ cells remain
functionally active. The result from the ART naı ¨ve and
patients on ART showed a positive correlation with the
frequencyoftetramer-bindingcells(R ¼ 0:692;p ¼ 0:0266
and R ¼ 0:930; p ¼ 0:0073; respectively) (data not shown)
and IFN-g producing cells by the ICC assay (R ¼ 0:887;
p ¼ 0:0006andR ¼ 0:934;p ¼ 0:0064;respectively)(data
not shown). Interestingly, a negative correlation was
observed between the frequency of IFN-g producing
tetramerþ T cells and absolute CD4þ T cell count in the
ART naı ¨ve (R ¼ 0:657; p ¼ 0:0392) (data not shown)
whereas a positive correlation withabsoluteCD4count was
observedinpatientsonART(R ¼ 0:895;p ¼ 0:0159)(d at a
not shown). This indicates that a signiﬁcant number of
functional CTL exist even in the absence of circulating
CD4þ Tc e l l s .
Attempts to Reconstitute the IFN-g Response of the
A11 Nef Tetramer1 CD81 T Cells
While controversy continues to exist on the quantitative
aspects of the frequency of HIV-1 antigen speciﬁc CD8þ
dysfunctional cells among the viral peptide bearing
tetramerþ cells, most if not all these studies have to large
extent been performed on patients on a variety of anti-
retroviral therapies. Such therapies have included protease
inhibitors in some patients not others. It was reasoned that
one of the reasons for such discrepant results could be
the effect of such anti-viral drugs on the immune
parameters being measured, in particular, the effect
protease inhibitors would have on antigen processing
FIGURE 2 Flow cytometric four-colour analysis of CD3þ CD8þ T cell from unstimulated control (A), SEB stimulation (B) and peptide stimulation
(C and D). Upper left quadrant(IFN-g2 /tetramerþ ); upper right quadrant (IFN-gþ / tetramerþ ); lower left quadrant(IFN-g2 /tetramer-); lower right
quadrant (IFN-gþ /tetramer2 ). The percentage of IFN-g producing tetramerþ T cells was calculated within the tetramerþ population (square region)
as shown in Fig. 2D.
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using PBMCs samples from a cohort of HIV-1 infected
patients with no prior history of ART. Results of the
studies as shown above clearly document the marked
decrease in the ability of a signiﬁcant frequency of the
A11nef tetramerþ cells to synthesize IFN-g. Thus, these
results conﬁrm previous ﬁndings that document such
HIV-1 antigen positive CD8þ T cell dysfunction
(Goepfert et al., 2000; Shankar et al., 2000; Kostense
et al., 2001). In efforts to delineate potential mechanism(s)
that maybe contributing to such dysfunction, a select
number of samples ðn ¼ 3Þ from the same cohort of HIV-1
infected HLA-A*1101 patients from whom sufﬁcient
PBMCs samples could be obtained (P19, P38, P46) were
ﬁrst stained with the same A11nef tetramer reagent and
then cultured in vitro with the same Nef peptide in the
presence or absence of a number of cytokines/agents
previously thought to enhance or suppress prototype TH1
like (in this case IFN-g) immune function and/or
antibodies against cytokines thought to suppress TH1
prototype immune function. The enhancing cytokines/
agents included IL-2, IL-12, allogeneic irradiated PBMCs
and the CD40L stimulating antibody. The suppressing
cytokine speciﬁc antibodies included anti-TGF-b, TNF-a
and IL-10 which were combined and used as a cocktail
due to the paucity of the cell sample. As seen in Fig.3 ,
whereas incubation of aliquots of the PBMCs with IL-2,
allogeneic cells and anti-CD40L antibody led to partial
immune reconstitution, incubation with IL-4, IL-12 or the
cocktail of anti-TGF-b, TNF-a and IL-10 antibodies
failed to demonstrate any signiﬁcant augmenting effect.
Recently, there has been a renewed interest on a
potential role of CD4þ , CD25þ regulatory T cells in the
regulation of immune responses (Shevach et al., 2001).
It was thus reasoned that such phenotypic cells could
potentially play a role in regulating the response of
the A11Nef tetramerþ cells in their ability to synthesize
IFN-g upon challenge with the cognate nef peptide.
Unfractionated or CD4 depleted PBMCs from 2 HIV-1
HLA-A*1101 patients were subjected to analysis for
A11Nef tetramerþ cells that synthesize IFN-g using the
same technique as described above. Results of these
studies in fact showed a decrease in the frequency of
A11Nef tetramerþ CD3þ CD8þ cells that could
synthesize IFN-g (26.4 and 27.8% in unfractionated and
18.2 and 12.9%, respectively, in the CD4 depleted
cultures). These data, although obtained on only 2
patients, support the view that the dysfunction is likely
not due to Treg CD4þ T cells and the presence of CD4þ
T cells may be required for optimal HIV-1 peptide speciﬁc
response by the CD8þ T cells. It is recognized that the
role of Treg cells could be better assessed by selective
depletion of only the CD4þ CD25þ cells, however,
once again, the paucity of cell numbers precluded such
experimentation.
DISCUSSION
A number of studies have been conducted aimed at
deﬁning the presence/absence and relative frequency of
HIV-1 speciﬁc CTLs in patients at varying stages of HIV-1
infection (Carmichael et al., 1993; Rinaldo et al., 1995).
There has been a general consensus with regards to some
issues and not others. Thus, it is generally accepted that
there is a readily recognizable and at times robust HIV-1
speciﬁc CTL response during and shortly after the acute
infection period (Koup et al., 1994; Borrow et al., 1994).
In general, there is also a consensus that there is a gradual
loss of HIV-1 speciﬁc CTLs with progression to disease
and loss of CD4þ T cells (Carmichael et al., 1993; Klein
et al., 1995; Rinaldo et al., 1995). Finally, data do support
the view that LTNP maintain a readily recognizable and
detectable level of HIV-1 speciﬁc CTLs population which
FIGURE 3 Reconstitution of the HIV-1 Nef peptide speciﬁc IFN-g synthesizing response by A11Nef peptide tetramerþ CD8þ T cells from HIV-1
infected patients.
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patients (Klein et al., 1995; Harrer et al., 1996a,b).
Whereas a large number of these ﬁndings were based on
functional CTLs assays, the advent of peptide speciﬁc
effector cell detection using tetramer technology
provided a re-examination of the concepts above.
Thus, some studies utilizing immunodominant peptides
of either HIV-1 Env, Gag, or Nef to prepare HLA-tetramer
reagents to detect CD8þ MHC class I restricted
HIV-1 speciﬁc CTLs, appeared to suggest that select
patients appeared to progress to disease despite the
presence of signiﬁcant numbers of HIV peptide speciﬁc
tetramerþ cells (Spiegel et al., 2000). Other studies,
however, appeared to show a relatively good correlation
between the presence of select HIV-1 peptide speciﬁc
functional HIV speciﬁc CTLs and the frequency of the
same HIV-1 peptide speciﬁc tetramer binding cells
(Ogg et al., 1998; Appay et al., 2000; Goulder et al.,
2000). The utilization of the peptide speciﬁc ICC assay as
a correlate of a functionally identical peptide speciﬁc CTL
assay provided some clues as to the potential reasons for
the discrepant results. Thus, it appears that not all peptide
tetramerþ cells in the PBMCs of some HIV infected
patients synthesize IFN-g upon incubation with the same
speciﬁc peptide. One of the explanations provided for
these ﬁndings was that while the frequency of HIV peptide
speciﬁc CD8þ T cells are maintained, a large number of
them basically become dysfunctional. Since these ﬁndings
were made on patients with low or undetectable level of
plasma viremia, a role for viral load was discounted as a
potential reason for these ﬁndings. It was also reasoned
that these ﬁndings could be secondary to the inﬂuence of
the anti-retroviral drugs that most if not all the patients
were taking during the studies performed. Several anti-
retroviral drugs specially the protease inhibitors, have
been shown to inﬂuence immune responses (Andre et al.,
1998; Chougnet et al., 2001; Gruber et al., 2001; Stranford
et al., 2001) and thus their involvement could be easily
envisaged. These thoughts formed the basis for the
rationale of the studies performed herein. Thus, PBMCs
samples were obtained from the 2 selected groups of
HIV-1 infected patients following careful screening of the
history of these patients for levels of plasma viral loads
and the use of anti-retroviral drugs. Thus, while the
plasma viral loads were .10,000 viral copies/ml of
plasma in the ART naı ¨ve group, the levels were ,50
copies/ml of plasma of the patients on ART. The data on
the history of anti-retroviral drug use by the drug naive
HIV-1 infected patients were reasoned to be highly
reliable since the availability of anti-retroviral drugs is
highly limited in this study population. Thus, these
samples from these 2 groups of patients provided samples
that represented patients with relatively high viral loads
with no history of ART and patients with low to
undetectable levels of plasma viremia and a recorded
history of ART.
Several potential mechanisms could be reasoned to be
the basis of such impaired function. Thus, this impaired
function may due to inappropriate activation of
these cells. The down-regulation of CD3z and
CD28 has been previously observed in HIV-speciﬁc
CD8þ tetramerþ T cells (Trimble et al., 2000). These
molecules play an important role in T cell activation.
The loss of these molecules in HIV-speciﬁc CTLs may
cause a defect by providing insufﬁcient and/or sub-
optimal activation signals to produce a potent effector
function. Another possible explanation is the loss of help
from CD4þ T cells due to the depletion of CD4þ T cells
during the chronic phase of viral infection which leads to
uncontrolled viral replication even though CTL responses
have been shown not to require CD4þ T cells during
primary infection in select murine models (Zajac et al.,
1998). A study of samples from HIV-1 infected patients
showed a positive correlation between HIV-speciﬁc CTL
precursor frequency and antigen speciﬁc CD4þ T cell
proliferative response (Kalams et al., 1999). Moreover,
another studyshowed that a loss of IFN-g producing CTLs
correlated with declining CD4þ T cells counts indicating
that CD4þ T cells loss in HIV infection may cause CTL
dysfunction by the lack of a helper signal for appropriate
activation of HIV-speciﬁc CTLs (Kostense et al., 2002).
In the studies reported herein, we found a negative
correlation between the frequency of IFN-g producing
tetramerþ T cells and absolute CD4þ T cell count in the
ART naive patients. These data suggest that even when
there is a signiﬁcant loss of CD4þ T cells during HIV
infection, a signiﬁcant frequency of HIV-speciﬁc CTLs
are maintained and remains functionally conserved. This
result is in agreement with previous studies, which showed
a high frequency of HIVand CMV-speciﬁc CTLs detected
by peptide–tetramer complexes in the absence of
circulating peripheral CD4þ T cells (Spiegel et al.,
2000). The presence of a signiﬁcant frequency of HIV-
speciﬁc CTLs in the recirculating pool of PBMCs may be
due to a loss of the ability of such cells to home into
infection sites such as lymph nodes, which is secondary to
the lack of the expression of lymphoid homing molecules
such as CCR7 and CD62L (Chen et al., 2001). However,
the precise mechanisms that maintain the existence of
such pools of HIV-speciﬁc CTLs in the absence of optimal
levels of CD4þ T cells remains to be elucidated.
In contrast to the ART naı ¨ve patients, the results also
showed a positive correlation between the frequency
of IFN-g producing tetramerþ T cells and absolute
CD4þ T cell count in the patients on ART even though
no signiﬁcant difference of HIV-speciﬁc CTLs were
observed between these two groups of patients. This result
is in agreement with previous studies, which showed the
loss of IFN-g producing tetramerþ T cells correlated
with declining CD4þ T cell count (Kostense et al.,2002).
The different results observed between these two groups
of patients might be due to the effect of ART on the
distribution of circulating CD4þ and CD8þ T cell after
therapy. However, the relationship between HIV-speciﬁc
CTLs and CD4þ T cells before and during ART are
unclear and remains to be elucidated.
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ﬁndings of previous studies (Goepfert et al., 2000;
Shankar et al., 2000; Kostense et al., 2001). Thus, whereas
signiﬁcant numbers of HIV-1 Nef immunodominant
peptide speciﬁc CTLs were observed in the PBMCs of
these anti-retroviral drug naı ¨ve population, the frequency
of IFN-g synthesizing cells were a log lower in absolute
value as compared to the absolute values for the same
peptide speciﬁc tetramer binding cells (see Fig. 1A and
Table II). This was also true when one examined
the absolute number of IFN-g synthesizing cells by the
tetramerþ CD8þ T cells in these patients, although the
ICC assay was a lot more sensitive than the ELISPOT
assay giving values which showed a 5-fold decrease by the
ICC as compared to 10-fold by the ELISPOT assay. What
was not clear from these data was whether these decreased
values of HIV-1 speciﬁc functional cells is due to
an intrinsic reversible/irreversible defect among the
CD8þ T cells or that heterogeneity exists among clonal
population of HIV-1 peptide speciﬁc CTLs. Since the
tetramerþ cells express the same relative density of TCR
(see Fig. 2D), it is likely that the functional inability is not
due to differences in afﬁnity among the tetramerþ cells.
These thoughts prompted the preliminary reconstitution
studies reported herein.
Attempts were made to determine the potential
mechanisms for such dysfunction. First of all, it was
reasoned that such dysfunction could merely be a
reﬂection of a chronic viral infection and as such would
be manifest for all chronic viral infections. While this
issue is difﬁcult to appropriately address in humans, the
chronic LCMVinfected mice provides a reasonable model
to address this issue. As described elsewhere (Welsh,
2001), however, this was not the case since the frequency
of IFN-g synthesizing LCMV speciﬁc CD8þ T cells did
not decrease during the chronic infection period. Thus,
although a more detailed study of a number of other
chronic viral infections needs to be performed, parti-
cularly in humans, it is possible that the dysfunction noted
herein is likely to be secondary to the immunodeﬁcient
state of such HIV-1 infected patients. Secondly, it was
reasoned that such dysfunction could be secondary to an
abnormal cytokine mileu. To address this issue, a study
was carried out whereby PBMCs from 3 HLA-A*1101
positive HIV-1 infected patients were cultured with
cytokine and/or agents known to augment TH1 prototype
immune responses (such as IL-2, IL-12, anti-CD40L,
allogeneic cells) and neutralize immune suppressive
cytokines (such as TGF-b, TNF-a and IL-10). Results of
these studies showed that whereas partial immune
reconstitution (herein utilized to signify increase in the
frequency of A11Nef tetramerþ cells to synthesize
IFN-g) was noted with the use of IL-2, CD40L antibody
and allogeneic cells, such augmented immune responses
were not noted with the use of IL-12, IL-4 or a cocktail of
anti-TGF-b, TNF-a and IL-10 antibodies. One could
argue that the use of a single concentration of the reagents
utilized and the short incubation time may not be optimal
to observe desired effects. While such a critique is clearly
reasonable, with the limited availability of patient sample
and the observation of clearly positive augmentation by
some of these agents, minimally provides some clues as to
the potential mechanisms involved. It is intriguing that
whereas anti-CD40L did appear to augment IFN-g
response, IL-12 failed to demonstrate any effect, although
signals provided to CD4þ T cells by these agents are both
generated by APCs. It is possible that the differences in the
signals induced by IL-12 as compared with CD40L
ligation could account for the data observed. Since the
pathways by which such signaling is mediated is at least
partially known, it would be important in the future to
further dissect out the molecular mechanisms by which the
CD40L induced pathway is functional but not the IL-12.
In the latter case a recently described assay for STAT4 and
phosphorylated STAT4 would be a reasonable initial
approach (Uzel et al., 2001).
It is important to note that none of the antibodies
against the putative immune suppressing cytokines
appeared to inﬂuence the IFN-g response of the A11nef
tetramerþ CD8þ T cells. Although preliminary, these
data appear to suggest that there is limited if any role for
such cytokines in modulating the IFN-g response of the
antigen speciﬁc CD8þ T cells, at least in vitro. Finally,
the results of the CD4þ T cell depletion prior to analysis
of the A11Nef tetramerþ cells to synthesize IFN-g is of
interest. Thus, while a prominent immunoregulatory role
for the CD4þ CD25þ Treg cells has been documented
in a wide variety of animal models, its role in human
immune function remains to be fully elucidated. In the
studies reported herein, there does not appear to be a role
for such Treg cells. However, it is recognized that results
of such an assay need to be interpreted with caution, since
removal of all CD4þ T cells could have also
eliminated CD4þ T helper function mediated by the
few CD4þ T cells remaining in these patients. Speciﬁc
depletion of the CD4þ CD25þ but not the remainder of
the CD4þ T cell pool would have been an ideal for
properly interpreting the data. Unfortunately, the
restricted number of cells did not permit such a study.
Future studies aimed at performing such a study are
currently underway. We submit that the cellular and
molecular basis of antigen speciﬁc CD8þ Tc e l l
dysfunction in HIV-1 infection needs to be more fully
elucidated to design platforms for full immune reconstitu-
tion studies in human HIV-1 infected patients.
In summary, the data presented conﬁrms the previous
ﬁnding of the presence of a signiﬁcant frequency of HIV-1
antigen speciﬁc dysfunctional CD8þ T cells in the
circulation of chronically HIV-1 infected patients. Such
dysfunction was not determined to be secondary to either
the absence of circulating antigen or due to the use of
ART. The mechanisms by which such functionally
inactive CD8þ T cells survive for prolonged periods of
time remains to be elucidated. Such dysfunction could be
partially reconstituted by the exogenous addition of IL-2,
allogeneic cells and anti-CD40L but not by IL-12, IL-4 or
N. ONLAMOON et al. 296by the addition of a cocktail of antibodies against TGF-b,
TNF-a and IL-10. These data provide some initial insights
on the avenues for further studies aimed at delineating the
mechanisms of immune dysfunction in HIV-1 infected
patients.
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